絞り込み

16645

広告

Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.

著者 De Caterina R , Brüggenjürgen B , Darius H , Köhler S , Lucerna M , Pecen L , Renda G , Schilling RJ , Schliephacke T , Zamorano JL , Le Heuzey JY , Kirchhof P
Arch Cardiovasc Dis.2017 Sep 20 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (35view , 0users)

Full Text Sources

Medical

Miscellaneous

Non-vitamin K antagonist oral anticoagulants (NOACs) are being introduced for stroke prevention in non-valvular Atrial Fibrillation (AF), and promise to be accepted better than Vitamin K Antagonists (VKAs) by patients, improving their Quality of Life (QoL).
PMID: 28942115 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード